“People Are Buying More, but Commercial Margins Continue to Be Sacrificed to Keep Operations Running,” Conindustria Recently Warned. Photograph: ConsultorSalud
Guacamaya, August 4, 2025. The Chamber of the Pharmaceutical Industry (Cifar) reported a year-on-year growth of 23.4% in the sector during the first half of 2025. According to data shared with international agencies, increased distribution of medications and price stability have contributed to the expansion of this market compared to figures from previous years.
Between January and June 2025, approximately 190.22 million medications were delivered to pharmacies across the country, a notable increase from the 154.12 million distributed during the same period last year. In June alone, the pharmaceutical market grew by 39% compared to June 2024, rising from 28.58 million to 39.74 million units, according to Cifar data.
The chamber, which includes 11 pharmaceutical plants and 7 representative offices, attributes this growth to the renewed leadership of domestic manufacturing laboratories in production and internal supply. Additionally, the industry group states that Venezuela has the lowest average price per unit in Latin America, at $4.11.
However, despite the sustained recovery in pharmaceutical sales, the industry continues to face structural challenges such as limited access to credit and declining household purchasing power. In response, Tito López, president of Cifar, has emphasized the need to restore tax credits so that factories can continue operating.
According to projections from the pharmaceutical guild, a 17.7% increase is expected compared to last year, with up to 380 million units distributed. If this forecast is met, it would mark two consecutive years of growth for an industry that, after years of contraction, managed to increase production by 35.3% in 2024 and by 28.7% in the first quarter of this year, according to Conindustria
